Curative effect of Shenling Baizhu Powder combined with bifidobacterium triplet on functional constipation with spleen deficiency in children

doi:10.3877/cma.j.issn.2095-2015.2025.01.015

Abstract

Abstract:

Objective

To explore the curative effect of Shenling Baizhu Powder combined with bifidobacterium triplet on functional constipation with spleen deficiency in children.

Methods

A total of 165 children with functional constipation with spleen deficiency treated in First Hospital of Yulin from March 2021 to June 2024 were prospectively selected, and 140 children were finally included as study objects after screening with inclusion and exclusion criteria. The children were divided into control group(bifidobacterium triple viable tablet treatment, n=70) and study group (Shenling Baizhu Powder combined with bifidobacterium triple viable tablet treatment, n=70) by computer random allocation method. The clinical efficacy, main symptom score, traditional Chinese medicine (TCM) syndrome score, serum nitric oxide (NO) and the intestinal neurotransmitter substance P (SP), occurrence of adverse reactions (rash,nausea, vomiting, diarrhea) and recurrence of the two groups were compared.

Results

The total effective rate of the study group (87.14%) was significantly higher than that of the control group (71.43%) (P＜0.05).After treatment, the main disease score and TCM syndrome score of the study group and the control group were significantly decreased, and the decreased of the study group was more significant (P＜0.05). After treatment, NO decreased and SP increased in the two groups, and the changes in the study group were greater (P＜0.05). There was no significant difference in the adverse reaction rate between the study group(12.86%) and the control group (15.71%) (P＞0.05). The recurrence rate of study group (8.57%) was significantly lower than that of control group (18.57%) (P＜0.05).

Conclusion

Shenling Baizhu Powder combined with bifidobacterium triplet has significant therapeutic effect on functional constipation of spleen deficiency type in children, which can effectively improve defecation and gastrointestinal function, reduce the possibility of recurrence, and has good safety, which can be used for clinical promotion and application.

Key words: Functional constipation, Spleen deficiency type, Shenling Baizhu Powder, Bifidobacterium triple viable tablet, Traditional Chinese medicine syndrome score

Shengxia He, Kaina Yang, Pu Li. Curative effect of Shenling Baizhu Powder combined with bifidobacterium triplet on functional constipation with spleen deficiency in children[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2025, 15(01): 73-77.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2025.01.015

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2025/V15/I01/73

Figures/Tables 4

References 24

[1]	Black CJ, Ford AC. Chronic idiopathic constipation in adults:epidemiology, pathophysiology, diagnosis and clinical management[J]. Med J Aust, 2018, 209(2): 86-91.
[2]	施敏, 夏旭婷, 廖陈敏, 等. 基于肠道菌群研究枳术丸治疗脾虚证慢传输型便秘的作用机制[J]. 中国微生态学杂志, 2023, 35(3):249-256.
[3]	Barberio B, Judge C, Savarino EV, et al. Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021,6(8): 638-648.
[4]	张慧君, 刘剑锋, 陈国雁, 等. 参苓白术散联合阿泰宁对脾虚湿困型肠息肉术后患儿的临床疗效[J]. 中成药, 2024, 46(3): 1050-1053.
[5]	Marc A. Benninga, Samuel Nurko, et al. Rome IV standard for functional gastroenterology in children[J]. Chin J Pediatr, 2017,55(1): 4-14.
[6]	江育仁, 张奇文. 实用中医儿科学[M]. 上海: 上海科学技术出版社, 2005.
[7]	周兆馨, 陈洁, 陈镜如, 等. 运脾润通汤治疗儿童功能性便秘脾虚气滞证病例系列研究[J]. 北京中医药, 2024, 43(2): 216-219.
[8]	中国中西医结合学会消化系统疾病专业委员会. 胆石症中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018,26(2): 132-138.
[9]	林胜. 芪术润下汤治疗气阴两虚型功能性便秘患儿的临床研究[J]. 中国卫生标准管理, 2022, 13(5): 121-125.
[10]	van Mill MJ, Koppen IJN, Benninga MA. Controversies in the Management of Functional Constipation in Children[J]. Curr Gastroenterol Rep, 2019, 21(6): 23.
[11]	郑金粟, 朱宏勋, 权红. 加味和肝汤治疗肝郁脾虚型功能性便秘的临床疗效及对血清肠神经递质的影响[J]. 北京中医药, 2022(3):238-242.
[12]	刘四香, 黄永坤, 王明英, 等. 功能性便秘患儿的肠道菌群分析及治疗干预[J]. 昆明医科大学学报, 2022, 43(3): 123-127.
[13]	张忠涛. 中国结直肠外科20年回顾与展望[J]. 中华消化外科杂志, 2022, 21(1): 53-56.
[14]	何宝佳, 魏蔚, 张艳华, 等. 黄秋葵粗多糖对脾虚便秘模型小鼠的作用及机制研究[J]. 中药新药与临床药理, 2022, 33(3): 313-318.
[15]	Tran DL, Sintusek P. Functional constipation in children: What physicians should know[J]. World J Gastroenterol, 2023, 29(8):1261-1288.
[16]	申正新, 唐会梅, 陈良. 便通片联合双歧杆菌乳杆菌三联活菌片治疗慢性功能性便秘的临床研究[J]. 现代药物与临床, 2023,38(9): 2279-2283.
[17]	Jokela R, Pärnänen KM, Ponsero AJ, et al. A cohort study in family triads: impact of gut microbiota composition and early life exposures on intestinal resistome during the first two years of life[J]. Gut Microbes, 2024, 16(1): 2383746.
[18]	袁吉林, 史忠瑞, 翟真真, 等. 浮针疗法联合双歧杆菌三联活菌胶囊治疗功能性便秘疗效观察[J]. 现代中西医结合杂志, 2024,33(6): 829-832.
[19]	江学良. 益生菌制剂在消化系统中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(2): 49-53.
[20]	李晶, 杨亚峰, 王晓燕. 三黄承气膏穴位贴敷治疗小儿功能性便秘的疗效观察[J]. 中医药导报, 2023, 29(6): 98-100.
[21]	武妍琳, 刘喜平, 贾育新, 等. 参苓白术散对肠道菌群失调幼鼠肺部免疫炎症反应的影响[J]. 中国中医药信息杂志, 2022, 29(11):79-85.
[22]	张慧君, 刘剑锋, 陈国雁, 等. 参苓白术散联合阿泰宁对脾虚湿困型肠息肉术后患儿的临床疗效[J]. 中成药, 2024, 46(3): 1050-1053.
[23]	张全文, 冯硕, 夏世信. 参苓白术散治疗腹泻型肠易激综合征对症状, 脑肠肽, IFN-γ, IL-8水平的影响[J]. 中药材, 2023, 46(4):1030-1033.
[24]	吴胜志, 史小克, 陈益飞, 等. 参苓白术散结合双歧杆菌四联活菌片对肥胖症患儿代谢状况和脂肪因子及肠道菌群平衡影响的前瞻性研究[J]. 中国微生态学杂志, 2022, 34(7): 833-839.

组别	例数	显效	有效	无效	治疗总有效率
研究组	70	36(51.43)	25(35.71)	9(12.86)	61(87.14)
对照组	70	22(31.43)	28(40.00)	20(28.57)	50(71.43)

组别	例数	显效	有效	无效	治疗总有效率
研究组	70	36(51.43)	25(35.71)	9(12.86)	61(87.14)
对照组	70	22(31.43)	28(40.00)	20(28.57)	50(71.43)

组别		例数	大便频次	排便时间	大便性状	排便困难	排便疼痛	中医证候积分
研究组	治疗前	70	1.32±0.50	1.56±0.82	1.98±0.93	2.01±0.88	1.84±0.72	8.54±3.15
对照组		70	1.30±0.45	1.60±0.81	1.94±0.90	1.98±0.86	1.86±0.71	8.41±3.20
研究组	治疗后	70	0.65±0.23^*	0.74±0.30^*	0.82±0.34^*	0.80±0.30^*	0.70±0.38^*	3.26±0.58^*
对照组		70	0.86±0.33^*	0.85±0.31^*	0.98±0.38^*	0.92±0.39^*	0.88±0.41^*	4.43±0.67^*
t _{治疗前/治疗后}			0.304/5.764	0.290/2.133	0.259/2.625	0.204/2.040	0.166/2.694	0.242/11.050
P _{治疗前/治疗后}			0.762/＜0.001	0.772/0.035	0.796/0.010	0.839/0.043	0.869/0.008	0.809/＜0.001

组别		例数	大便频次	排便时间	大便性状	排便困难	排便疼痛	中医证候积分
研究组	治疗前	70	1.32±0.50	1.56±0.82	1.98±0.93	2.01±0.88	1.84±0.72	8.54±3.15
对照组		70	1.30±0.45	1.60±0.81	1.94±0.90	1.98±0.86	1.86±0.71	8.41±3.20
研究组	治疗后	70	0.65±0.23^*	0.74±0.30^*	0.82±0.34^*	0.80±0.30^*	0.70±0.38^*	3.26±0.58^*
对照组		70	0.86±0.33^*	0.85±0.31^*	0.98±0.38^*	0.92±0.39^*	0.88±0.41^*	4.43±0.67^*
t _{治疗前/治疗后}			0.304/5.764	0.290/2.133	0.259/2.625	0.204/2.040	0.166/2.694	0.242/11.050
P _{治疗前/治疗后}			0.762/＜0.001	0.772/0.035	0.796/0.010	0.839/0.043	0.869/0.008	0.809/＜0.001

组别	例数	一氧化氮(nmol/mL)		肠神经递质P物质(pg/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后
研究组	70	27.54±8.33	15.62±3.17^*	163.77±15.89	189.78±17.54^*
对照组	70	28.62±7.59	19.78±3.88^*	160.85±14.66	173.45±16.32^*
t		0.802	6.947	1.130	5.703
P		0.424	＜0.001	0.260	＜0.001

Please choose a citation manager

Content to export